| Followers | 169 |
| Posts | 8967 |
| Boards Moderated | 0 |
| Alias Born | 01/24/2011 |
Monday, March 14, 2016 4:11:40 PM
It's all due to a cannabis pharma company
You know that English pharmaceutical company that's been testing a CBD-based anti-epilepsy drug? Before today's open it announced very good results from a late-stage test of the drug, and so was up 120% today.
Took a lot of other cannabis-related companies along for ride.
One crappy little company with CBD in its stock symbol, "cannabis" in its name and $6400 in 3Q/15 revenues rose 241% today.
Even an industrial hemp company that doesn't have a working decorticator plant, and won't be able to process hemp for a couple of growing seasons due to the law allowing growing in in that state not taking effect for awhile, saw a 25% boost in its stock price.
You know that English pharmaceutical company that's been testing a CBD-based anti-epilepsy drug? Before today's open it announced very good results from a late-stage test of the drug, and so was up 120% today.
Took a lot of other cannabis-related companies along for ride.
One crappy little company with CBD in its stock symbol, "cannabis" in its name and $6400 in 3Q/15 revenues rose 241% today.
Even an industrial hemp company that doesn't have a working decorticator plant, and won't be able to process hemp for a couple of growing seasons due to the law allowing growing in in that state not taking effect for awhile, saw a 25% boost in its stock price.
"Soylent Green is people!!!"
Detective Robert Thorn: Telling uncomfortable truths since 2022
DRT is Charleton Heston's character in the 1973 movie, Soylent Green, set in the year 2022, and is not my real name
Recent CVSI News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:04:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 09:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 08:06:03 PM
- CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results • ACCESS Newswire • 03/26/2026 08:00:00 PM
- CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026 • ACCESS Newswire • 03/24/2026 09:00:00 PM
- CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth • ACCESS Newswire • 03/10/2026 09:00:00 PM
- CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness • ACCESS Newswire • 02/26/2026 01:30:00 PM
- CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD • ACCESS Newswire • 12/23/2025 12:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:19:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:04:08 PM
- CV Sciences, Inc. Reports Third Quarter 2025 Financial Results • ACCESS Newswire • 11/13/2025 09:00:00 PM
- CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025 • ACCESS Newswire • 11/10/2025 11:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:24:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 09:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2025 08:01:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2025 08:50:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2025 08:01:33 PM
